Noticias de VIR_US | Rava Bursátil

14/10/2026 VIR_US — Pharmaceutical Executive

Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers

Gilead y Vir Biotechnology inician una colaboración de 1.870 millones de dólares para descubrir tres activadores de células T de doble máscara PRO-XTEN destinados a tumores sólidos.

14/10/2026 VIR_US — MarketScreener

Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors

14/10/2026 VIR_US — Yahoo Finance

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

14 de octubre () - Vir Biotechnology dijo el miércoles que había firmado un acuerdo de colaboración por valor de hasta 1.880 millones de dólares con Gilead ‌Sciences para descubrir y desarrollar nuevos tratamientos contra el cáncer para tumores sólidos.

14/10/2026 VIR_US — Yahoo Finance

Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors

Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead Sciences (GILD)

14/10/2026 VIR_US — Investing.com

Vir Biotechnology partners with Gilead on cancer therapies By Investing.com

14/10/2026 VIR_US — Investing.com

Vir Biotechnology partners with Gilead on cancer therapies By Investing.com

14/10/2026 VIR_US — Seeking Alpha

Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs

14/10/2026 VIR_US — TipRanks

Vir Biotechnology seals major oncology alliance with Gilead

14/10/2026 VIR_US — Investing.com

Vir Biotechnology partners with Gilead on cancer therapies By Investing.com

14/10/2026 VIR_US — Kalkine Media

Vir Biotechnology Sells 1.76 Million Shares to Gilead in $25M Stock Deal

14/10/2026 VIR_US — Simply Wall Street

Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions

14/10/2026 VIR_US — Business Wire

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

14/10/2026 VIR_US — Reuters

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

14/10/2026 VIR_US — MarketBeat

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next?

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Still a Buy?

13/10/2026 VIR_US — dars.gov.et

Vir Biotechnology (VIR) Slides 4.25% to $10.82 as Support at $10.28 Comes Into Focus - BPI Bear Confirmed

13/10/2026 VIR_US — Simply Wall Street

Vir Biotechnology (NasdaqGS:VIR) Stock Price

12/10/2026 VIR_US — Stocktwits

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

La compañía dijo que se espera que sus recursos actuales financien operaciones hasta el segundo trimestre de 2028.

11/10/2026 VIR_US — Yahoo Finance

Vir Biotechnology, Inc. (VIR) Stock forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

10/10/2026 VIR_US — Yahoo Finance

Vir Biotechnology, Inc. (VIR) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

10/10/2026 VIR_US — MarketBeat

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Here's What Happened

Vir Biotechnology (NASDAQ:VIR) Hits New 1-Year High - Should You Buy?